Henrik Möbitz

发表

Targeting cancer with small-molecular-weight kinase inhibitors.

D. Fabbro, G. Martiny-Baron, S. Cowan-Jacob, 2012, Methods in molecular biology.

Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.

M. Bock, Sunil K. Panigrahi, M. Ramachandra, 2022, Journal of medicinal chemistry.

Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors.

D. Bednarczyk, Y. Cho, S. Skolnik, 2022, Journal of medicinal chemistry.

Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides.

M. Staufenbiel, J. Rondeau, S. Desrayaud, 2013, Bioorganic & medicinal chemistry letters.

Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.

Jean-Michel Rondeau, Laura Jacobson, M. Staufenbiel, 2012, Journal of medicinal chemistry.

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

R. Tiedt, D. Guthy, C. Scheufler, 2019, ACS medicinal chemistry letters.

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Philipp Holzer, R. Tiedt, G. Caravatti, 2017, ACS medicinal chemistry letters.

Members of the genus Arthrobacter grow anaerobically using nitrate ammonification and fermentative processes: anaerobic adaptation of aerobic bacteria abundant in soil.

D. Jahn, M. Eschbach, H. Möbitz, 2003, FEMS microbiology letters.

The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain Fold*

N. Schmiedeberg, G. Fendrich, T. Troxler, 2015, The Journal of Biological Chemistry.

Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

G. Martiny-Baron, G. Fendrich, T. Troxler, 2016, Journal of medicinal chemistry.

The ABC of protein kinase conformations.

H. Möbitz, Henrik Möbitz, 2015, Biochimica et biophysica acta.

Type II Inhibitors Targeting CDK2.

C. Deane, S. Knapp, O. Fedorov, 2015, ACS chemical biology.

1 Type II inhibitors targeting CDK 2

C. Deane, S. Knapp, O. Fedorov, 2016 .

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma

A. Kauffmann, D. Ruddy, GiNell Elliott, 2020, Molecular Cancer Therapeutics.

Structural biology contributions to tyrosine kinase drug discovery.

D. Fabbro, S. Cowan-Jacob, H. Möbitz, 2009, Current opinion in cell biology.

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

D. Fabbro, W. Jahnke, G. Rummel, 2015, ACS medicinal chemistry letters.

Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors.

Clive McCarthy, Jean-Michel Rondeau, Marina Tintelnot-Blomley, 2011, Bioorganic & medicinal chemistry letters.

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.

T. Hu, Eugen Lounkine, Tamara J. Gilbert, 2018, Journal of medicinal chemistry.

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.

T. Hu, Eugen Lounkine, Tamara J. Gilbert, 2018, Journal of medicinal chemistry.

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Philipp Holzer, R. Tiedt, G. Caravatti, 2016, ACS Medicinal Chemistry Letters.

Changes in protein synthesis during the adaptation of Bacillus subtilis to anaerobic growth conditions.

D. Jahn, T. Hoffmann, R. Schmid, 2000, Microbiology.

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

R. Tiedt, C. Fernández, C. Scheufler, 2016, ACS medicinal chemistry letters.